Cite
HARVARD Citation
Ge, Y. et al. (2018). Alternative splice variants of DCLK1 mark cancer stem cells, promote self‐renewal and drug‐resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. International journal of cancer. 143 (5), pp. 1162-1175. [Online].